Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 17/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 17/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807606 | 0.93 | KCNK3 (0.59) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| Trifluoroacetic Acid SCHEMBL20587448 | 0.92 | KCNK3 (0.60) | KCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL31448504 | 0.92 | KCNK3 (0.59) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL22001471 | 0.87 | KCNK3 (0.58) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL19807471 | 0.82 | KCNK3 (0.62) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL22916250 | 0.81 | KCNK3 (0.53) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| Hydrochloric Acid SCHEMBL31448337 | 0.80 | KCNK3 (0.52) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL19807496 | 0.80 | KCNK3 (0.62) | KCNK3KCNK9 | |
| SCHEMBL22635923 | 0.80 | KCNK3 (0.78) | KCNK3KCNK9 | |
| SCHEMBL25425858 | 0.79 | KCNK3 (0.70) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | KCNK3 117/4885KCNK9 725/4885KDM4E 1380/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | KCNK3 135/4885KCNK9 793/4885KDM4E 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.